複合語候補ITC104

複合語スコア
herpes zoster5183.506266798
varicella zoster virus844.73314175926
incidence of herpes zoster247.94188319859
acute herpes zoster207.67493560408
prevention of herpes zoster136.02390012756
postherpetic neuralgia121.18240878588
antiviral therapy115.39564810414
episode of herpes zoster111.71086250133
treatment of herpes103.76616750019
n engl j med96.359922943661
acute pain92.919707492375
intravenous acyclovir72.376241554004
varicella zoster virus vasculopathy69.705940248073
episode of herpes67.398102831388
immunocompromised patients66.79578440913
pain of herpes zoster57.072232811117
live attenuated zoster vaccine56.947538877484
herpes zoster vaccine55.24745423471
oral acyclovir54.99090833947
active herpes zoster54.173494431106
herpes zoster ophthalmicus51.637323988487
herpes zoster presenting51.637323988487
clinical diagnosis of herpes zoster51.375113151333
acute episode of herpes zoster49.403876373697
varicella vaccine46.331687411531
use of herpes43.628299137764
severe pain42.560804659612
complications of herpes zoster42.051180674778
uncomplicated herpes41.814001326102
incidence of herpes41.684343947313
zoster vaccine41.666107508744
history of herpes zoster40.984571210074
treatment of herpes zoster40.984571210074
varicella zoster virus dna40.950757897684
herpes zoster rash40.082524921175
immunocompetent patients40.079761113877
zoster efficacy study39.417088182472
skin lesions38.934150409863
severe herpes38.791653025852
shingles vaccine38.170664872767
immunization practices37.951284151613
immunocompetent adults35.858543433572
recombinant zoster vaccine35.281898729777
had varicella35.204469471736
severity of herpes zoster34.127162990056
united states33.895612242702
severe herpes zoster33.762044091568
shingles prevention study group33.181441818535
varicella zoster vaccination32.846322030069
shingles prevention study32.449917580626
disseminated herpes32.061953638604
adjuvanted herpes zoster subunit vaccine31.77222345061
ann intern med31.141969833037
cases of herpes zoster31.006585322085
clin infect dis30.739889190125
acute retinal necrosis30.340013319898
disseminated herpes zoster29.734675012037
j infect dis29.575246175559
management of herpes zoster28.980468226666
subsequent herpes27.876000884068
disease control26.560366072808
therapy of herpes26.465878355799
acute herpes26.465878355799
early herpes zoster25.818661994244
recurrent herpes zoster25.818661994244
herpes zoster of childhood vaccination25.481160611561
et al25.234737164239
advisory committee24.973349415057
varicella zoster infection24.756751207287
dose of varicella vaccine24.5919113521
developed herpes zoster24.131548372928
diagnosing herpes zoster24.131548372928
episodes of herpes zoster24.131548372928
risk of herpes23.971901648529
cutaneous lesions of herpes zoster23.837907593557
herpes simplex virus23.469378262797
low-dose acyclovir23.424041119829
antiviral drugs22.925026663968
antiviral treatment22.62189070204
dissemination of varicella zoster virus22.328559072964
central nervous system21.568098473556
varicella zoster virus igg21.539883775495
varicella zoster virus transmission21.539883775495
transmission of varicella zoster virus21.539883775495
efficacy of zoster vaccine20.943453264666
possible varicella zoster20.91565822694
cutaneous healing of herpes zoster20.435204196548
harpaz r19.817003712138
varicella zoster virus retinitis18.776005282236
possibility of varicella zoster virus18.776005282236
zosteriform herpes simplex18.751775539312
family history of herpes zoster18.58255614553
oral antiviral therapy18.558378711077
varicella vaccination program18.367718043369
neuralgic pain18.350726547188
live attenuated varicella zoster virus vaccine18.111232638103
multifocal vasculopathy17.773539825992
live zoster vaccine17.640949364888
oral acyclovir therapy16.922206158072
cutaneous healing16.757054048864
percent of patients16.647165801151
history of zoster rash16.622829872088
disseminated zoster16.451644568508
influenza vaccine16.214401857684
zoster vaccine introduction16.201199197581
complication rates of herpes zoster16.198145541661
population-based study15.954887690835
vaccine group15.937130414921
oral treatment of herpes15.92383273608
differential diagnosis of herpes zoster15.833161478903
immune system15.79288815543
herpes simplex virus infection15.692026165119
duration of herpes15.424933085974
hours of lesion onset15.139721272633
history of varicella14.801656089846
chickenpox virus14.742090873255
ocular involvement14.325905783504
trigeminal zoster14.303746543502
ischemic lesions14.042083915924
introduction of zoster vaccination14.001630789771
safety of herpes13.938000442034
ocular complications13.759162513002
dermatomal zoster13.311136036748
localized zoster13.311136036748
live attenuated herpes13.197398237193
collaborative famciclovir herpes zoster study group12.637151777336
reactivation of varicella zoster virus increases12.493890175145
lass j12.183259109214
serious adverse events11.912482232343
schmader ke11.771323825531
tolerability of herpes11.720414607511
ocular inflammatory complications of herpes11.644979764212
new recombinant zoster vaccine11.47866721188
cutaneous lesions11.401079531087
mild pain11.384850195244
chronic pain11.384850195244
attenuated zoster vaccination coverage11.380099575338
live virus vaccine11.339001382966
neurologic complications11.269252989045
levin mj11.132630734855
childhood varicella11.066819197003
involved skin11.059433928161
childhood varicella vaccination11.029235690267
risk factors10.911407287692
years of age10.63659179389
wood mj10.63659179389
pain control10.594796911844
serologic testing10.583005244258
severe cases of herpes10.411483427417
acyclovir therapy10.047658220351
vaccination program9.8984640076795
previous zoster infection9.8636347990426
natural history of herpes9.8363850920969
central nervous system involvement9.7518455544798
potential severity of shingles9.7110004981407
typical symptoms of herpes9.5419832218598
health care9.4762744410752
everyday activities8.9442719099992
clinical practice8.8534553576026
late complication of herpes8.7632228696839
acyclovir halts progression of herpes8.587954697497
contralateral hemiparesis8.4852813742386
long-term persistence of zoster vaccine efficacy8.2824004707631
immunocompromised persons8.2390685756285
virus transmission8.157402714005
double-blind rct8.1324180324886
severe acute pain8.0542871296697
common indicator of herpes8.0103222774806
recombinant shingles vaccine7.999674446048
recurrent herpes simplex infection7.8851895052982
one rct7.770060192334
placebo-controlled trial7.7025702136862
subunit vaccine7.6673172509553
antiviral agents7.6416755546559
normal renal function7.5595262993692
visceral dissemination7.5446005780976
median follow-up7.5446005780976
systemic antiviral therapy7.4953678880267
immune status7.4448388728168
immunocompetent persons7.4155855021347
am j med7.3446842811871
live vaccine7.3256830029694
acute disease7.2794618755762
increased risk7.2742715251283
intravenous acyclovir therapy7.2287728000983
gilden d. neurological complications of varicella zoster virus reactivation7.226859299044
safety profile of varicella vaccine7.1606173454213
n z med j7.1599738063165
adverse ocular complications7.0752101004428
new lesion formation7.0752101004428
topical antiviral therapy7.0627845845626
oral analgesics6.9282032302755
johnson gr6.9009799013736
antiviral drug therapy6.8836401999298
virus replication6.8595306999877
duration of pain6.7694724277124
anti?varicella zoster virus igg antibody6.711207761057
bandlike rash6.700737917669
history of rash6.700737917669
imaging studies6.700737917669
varicella conflicts6.6874030497642
varicella seroprevalence6.6874030497642
varicella vaccinees6.6874030497642
other antiviral agents6.4942575804746
infectious disease specialist6.4062018950577
randomized trial of acyclovir6.4042231448869
pain control measures6.3079768610042
disseminated skin lesions6.3051701955963
trigeminal nerve6.2603383202932
clinical trials6.2603383202932
skin diseases6.2191767310173
lesions of patients6.160140576482
treatment of patients6.160140576482
concomitant antiviral therapy6.1326262302568
optimal antiviral therapy6.1326262302568
pain specialist6.1169088490625
sutphin j6.0916295546068
topical acyclovir6.0860922072299
antiviral medications6.0772008873526
pediatr infect dis j6.0671409520631
health history6.0548002080702
medicare part d6.0523429976916
skin changes6.014990027444
oxman mn6
cochrane database syst rev5.9906903399616
other complications5.9245132753306
low-dose oral acyclovir5.9036187547454
introduction of varicella vaccination programs5.8856619127654
severe allergy5.8856619127654
chickenpox vaccine5.8259012604879
skin biopsy5.7875960854994
2-shot varicella vaccine series5.7237619056446
antiviral drugs famciclovir5.6945454450228
physical examination5.5663153674275
retinal necrosis5.5663153674275
domingo j5.5044086707916
fingeroth j5.5044086707916
taylor j5.5044086707916
storek j5.5044086707916
marley j5.5044086707916
yang j5.5044086707916
crooks j5.5044086707916
listing j5.5044086707916
diez-domingo j5.5044086707916
decroix j5.5044086707916
pennella-vaughan j5.5044086707916
placebo group5.4711295994695
double-blind clinical trial5.4197492421882
around-the-clock pain control5.4146047111091
j clin virol5.399676491374
zhou m5.3706992285653
chlibek r5.3446902355676
mmwr morb mortal wkly rep5.3345372167932
other antiviral treatments5.3135289660276
confirmatory laboratory testing5.2733493302731
systematic review5.26429605181
severe ear pain5.252546217199
10.8 percent of vaccine recipients5.2169309429792
cunningham al5.1510191538028
pain resolution5.1436867236104
cessation of pain5.1436867236104
unrelenting pain5.1436867236104
pain relief5.1436867236104
zoster?associated pain5.1436867236104
prodromal pain5.1436867236104
persistent pain5.1436867236104
protracted pain5.1436867236104
prolonged pain5.1436867236104
zoster-associated pain5.1436867236104
controlled clinical trials5.1395931737013
development of skin lesions5.1170399378161
antiviral prophylaxis5.1102964409515
rash severity5.0914597900437
other serious complications5.0830352786163
studies of patients5.0099701392346
infectious diseases collaborative antiviral study group4.9736700491369
rash healing4.9242980521049
vaccine component4.8989794855664
family history of shingles4.8555002490703
had shingles4.8339055525626
clinical trials of rzv4.803747820704
pharmacokinetic characteristics4.7568284600109
contact dermatitis4.7568284600109
onset of rash4.7381372205376
bacterial superinfection4.6806946386414
patient information4.6806946386414
viral culture4.6806946386414
lack of awareness4.6806946386414
j cutan med surg4.6248450950756
other symptoms4.5799756509618
wilhelmus k4.5590141139096
larussa p4.5590141139096
kawai k4.5590141139096
injection site4.5590141139096
seasonal influenza vaccine4.5298688016454
inactivated influenza vaccine4.5298688016454
pine study4.4721359549996
combined acyclovir4.4496055862541
acyclovir fs4.4496055862541
clinical appearance4.4267276788013
late ocular inflammatory complications4.4111669921668
limited skin involvement4.4036997674034
skin disorders4.3976220398999
skin inflammation4.3976220398999
uninvolved skin4.3976220398999
balfour hh jr4.3644945438869
neurologic symptoms4.3558771746929
oral valacyclovir4.3558771746929
randomized trial4.331473541336
early pain management4.2975746072033
hwang sj4.2813902858562
liesegang t4.2813902858562
laboratory studies4.2813902858562
lal h4.2813902858562
serologic antibodies4.2813902858562
forszpaniak c4.2813902858562
johnson rw4.2813902858562
three clinical trials4.2796527757347
prospective clinical trials4.2796527757347
few isolated skin lesions4.256307646096
varicella-zoster virus dna4.2513258303959
nondrug measures4.2294850537623
acute disease phase4.2160379991699
zoe-70 study group4.2140337012003
zoe-50 study group4.2140337012003
serious adverse effects4.1998684144302
severe symptoms4.1617914502878
polymerase chain reaction4.1601676461038
adjacent dermatomes4.1195342878142
same time4.1195342878142
topical antiviral preparations4.1034303767613
infectious complications4.090623489235
potential ocular involvement4.0898524685786
shingles vaccines4.0648138508249
aggressive pain management4.0167507341439
betts rf4
large area of skin involvement3.9422986842475
increased skin sensitivity3.9398401381041
reynolds ma3.9359793425309
vaccination decisions3.9359793425309
bean b3.9359793425309
zhang jh3.9359793425309
tyring sk3.9359793425309
does childhood vaccination3.9148676411689
other possible symptoms3.9002320242577
central nervous system angiitis3.8587145198412
clear cause of shingles3.8538131016031
acute vision changes3.8538131016031
bacterial infection3.8512851068431
oral corticosteroids3.8336586254776
potential use3.8336586254776
postherpetic neuralgia?fewer patients3.822602143583
uncontrolled clinical trials3.8127371719878
hospital infection control practices advisory committee3.80596150237
such neurologic complications3.8027429028336
prednisone therapy3.7976578442319
common adverse effects3.7416573867739
whitley rj3.7224194364084
facial nerve3.7224194364084
percentage of children3.7224194364084
clinical outcome3.7224194364084
clinical presentation3.7224194364084
hospital rooms3.7224194364084
kim dk3.7224194364084
mckendrick mw3.7224194364084
first division3.7224194364084
seward jf3.7224194364084
anecdotal experience3.7224194364084
safety trial3.6423205736757
weakened immune system3.6342411856643
typical rash3.6002057436785
follow-up studies3.6002057436785
double-blind randomized controlled trial3.5520935491791
initial therapy3.5341188430494
improved therapy3.5341188430494
j am geriatr soc3.4904525651001
studies of recipients3.4820045452271
tricyclic antidepressants3.4641016151377
oral prednisone3.4641016151377
appropriate specialists3.4641016151377
age-related weakening3.4641016151377
air samples3.4641016151377
freezer storage3.4641016151377
laskin ol3.4641016151377
immunization schedule3.4641016151377
initial treatment3.4641016151377
diabetes mellitus3.4641016151377
steinberg sp3.4641016151377
use of corticosteroids3.4641016151377
bialek sr3.4641016151377
atypical presentations3.4641016151377
global perspective3.4641016151377
yawn bp3.4641016151377
foulks gn3.4641016151377
dworkin rh3.4641016151377
computed tomography3.4641016151377
sy ls3.4641016151377
national health3.4397906282504
population?based cohort study3.4199518933534
smith n3.3895612242702
aintablian n3.3895612242702
aggarwal n3.3895612242702
erskine n3.3895612242702
chen n3.3895612242702
typical skin eruption3.3818572012642
painful rash3.3503689588345
characteristic rash3.3503689588345
tyring s. open-label study of valacyclovir3.31445401734
retinal detachment3.3097509196469
cochrane review3.3097509196469
retinal tissue3.3097509196469
zostavax efficacy3.2531531233956
common adverse effect of rzv3.2531531233956
rzv group3.2531531233956
disease course3.2237097954706
risk of cancer3.2010858729437
¿ therapy3.1934368675747
randomised controlled trial3.1911262493545
health care professional3.1664800441388
89.8 percent3.1622776601684
97.2 percent3.1622776601684
61.1 percent3.1622776601684
99.2 percent3.1622776601684
8.9 percent3.1622776601684
19.3 percent3.1622776601684
9.0 percent3.1622776601684
17.5 percent3.1622776601684
66.5 percent3.1622776601684
51.3 percent3.1622776601684
1.4 percent3.1622776601684
25.7 percent3.1622776601684
90.6 percent3.1622776601684
systematic review of incidence3.14083560495
surveillance of vaccination coverage3.14083560495
use steroids3.1301691601466
successful treatment3.1301691601466
overlap of lesions3.1301691601466
u.s. adults3.1301691601466
thorough history3.1301691601466
nonhemorrhagic lesions3.1301691601466
susceptible immunocompromised persons3.0861636884341
limited cutaneous involvement3.0825813601419
97.3 percent of persons3.080070288241
many patients3.080070288241
cutaneous vesicles3.0628143136088
cerebral vasculopathy3.0628143136088
primary infection3.0628143136088
common complication3.0274001040351
wash rash3.0274001040351
itchy rash3.0274001040351
side effects3.0274001040351
prospective studies3.0274001040351
high efficacy3.0274001040351
clinical slide set3.0261714988458
painful red rash3.0182390421613
retinal biopsy specimens2.9937951655239
national immunization survey2.9937951655239
zhang d2.9906975624424
placebo-controlled trials2.9906975624424
placebo-controlled trial of oxycodone2.9506927476736
affected nerve2.9129506302439
optimal use2.9129506302439
systemic effects2.8925076085191
low risk2.8925076085191
9.4 percent of recipients2.8925076085191
16.5 percent of recipients2.8925076085191
percent of recipients2.8925076085191
betts r2.8716217110259
latent infection2.8502698827718
other medicines2.8502698827718
other benefits2.8502698827718
few other diseases2.8429702849739
visceral involvement2.8394115144337
zhou d2.8284271247462
hemiparesis contralateral2.8284271247462
1.5 g2.8284271247462
mental status changes2.8210130123402
vision changes2.8173132472613
common systemic effects2.8077989890847
kang y. vaccination coverage2.8057011040133
national immunization survey-child2.7981664143395
one side2.7831576837137
ophthalmic symptoms2.7831576837137
certain ophthalmologic complications2.766175108537
pathogenesis of diffuse disease2.7494592739972
department of health2.7355647997348
superior efficacy2.7355647997348
health professionals2.7355647997348
life-threatening secondary bacterial infection2.677321285993
meta-analysis of risk factors2.6546748825543
erythematous maculopapular rash2.6366746651365
use of gloves2.632148025905
dosing schedules2.632148025905
corticosteroid use2.632148025905
first dose2.632148025905
late complication2.632148025905
additional laboratory2.632148025905
blood test2.632148025905
as-needed dosing2.632148025905
afferent nerve2.632148025905
dosing regimen2.632148025905
contact isolation2.632148025905
clin res ed2.6207413942089
other signs2.5755095769014
hiv infection2.5755095769014
recommended immunization schedule2.5697965868507
control hosp epidemiol2.5697965868507
public health rep2.557759296802
intravenous antivirals2.5457298950218
histopathologic studies2.5457298950218
immunocompetent hosts2.5457298950218
topical corticosteroids2.5457298950218
alternate diagnosis2.5148668593659
examination of csf2.5148668593659
examination of links2.5148668593659
strokelike symptoms2.5148668593659
current symptoms2.5148668593659
gastrointestinal symptoms2.5148668593659
ophthalmic involvement2.4989993994394
cobo m2.4989993994394
characteristic funduscopic examination2.4928828716784
recent cochrane review2.4928828716784
intraocular inflammatory changes2.4643818583473
drug administration2.4494897427832
cunningham a2.4494897427832
supportive care2.4494897427832
facial muscle weakness2.4494897427832
o fhalloran a2.4494897427832
ifle r2.4147364027664
ashton r2.4147364027664
kay r2.4147364027664
farmer r2.4147364027664
schlag r2.4147364027664
gress r2.4147364027664
merlin r2.4147364027664
possible cause of tia2.401873910352
bill part d directly?and2.3784142300054
frequent dosing2.3784142300054
kruszon-moran d2.3784142300054
international blood2.3784142300054
yankey d2.3784142300054
immune response2.3784142300054
vista trial investigators2.3672935308725
anticholinergic side effects2.3490100793233
median duration2.3403473193207
age groups2.3403473193207
systemic reactions2.3403473193207
kurland mj2.3403473193207
involved dermatomes2.3403473193207
kenneth schmader2.3403473193207
diagnostic challenges2.3403473193207
dr. schmader2.3403473193207
magnetic resonance imaging2.334815148678
serious problems2.3003266337912
intravenous ganciclovir2.3003266337912
kim sj2.3003266337912
peripheral nerve palsies2.2894284851067
altered mental status2.2894284851067
primary care providers2.2894284851067
wade a2.2795070569548
potential benefits2.2795070569548
wollan p2.2795070569548
epidural injection2.2795070569548
vazquez m2.2581008643532
douha m2.2581008643532
babb-tarbox m2.2581008643532
heng m2.2581008643532
tomlinson m2.2581008643532
simultaneous involvement2.2581008643532
kovac m2.2581008643532
tomblyn m2.2581008643532
patel m2.2581008643532
kropff m2.2581008643532
permanent facial muscle weakness2.2461919979205
three 7-day regimens of famciclovir2.2427067839403
3.2 years2.2360679774998
3.1 years2.2360679774998
3.7 years2.2360679774998
tyring s2.2360679774998
nutrition examination survey2.2209061548523
active viral replication2.2209061548523
side ipsilateral2.2133638394006
second dose2.2133638394006
proximate cause2.2133638394006
young adults2.2133638394006
rare patient2.2133638394006
functional status2.2133638394006
levin l2.2133638394006
direct contact2.2133638394006
marrow research2.2133638394006
sacral area2.2133638394006
anecdotal reports2.2133638394006
weeks of onset2.2133638394006
improved preservation of vision2.1822472719434
mayo clin proc2.1822472719434
curr eye res2.1822472719434
mmwr recomm rep2.1544346900319
national institute of allergy2.1544346900319
single 0.65-ml dose2.1398263878673
resonant impurity states2.1398263878673
large surface area2.1398263878673
simplified dosing schedules2.1398263878673
cranial nerve ganglia2.1398263878673
increased sensitivity2.1147425268811
daily famciclovir2.1147425268811
lack of evidence2.1147425268811
diagnostic tests2.1147425268811
anti-tnf-alpha agents2.1147425268811
involved dermatome2.1147425268811
compared valacyclovir2.1147425268811
diagnostic procedures2.1147425268811
lack of need2.1147425268811
relative lack2.1147425268811
general information2.1147425268811
biol blood marrow transplant2.1039790110173
peripheral blood stem cells2.1039790110173
permanent pigment changes2.0927300685678
viral strain identification2.0757816311124
jumaan a2.0597671439071
moore k2.0597671439071
mruthyunjaya p2.0597671439071
potential pregnancy2.0597671439071
morton p2.0597671439071
saddier p2.0597671439071
sacral dermatomes2.0597671439071
hunter p2.0597671439071
herzer p2.0597671439071
strangfeld a2.0597671439071
sepkowitz k2.0597671439071
durham va medical center2.0597671439071
gnann jw2.0597671439071
bhaskaran k2.0597671439071
liebhaber a2.0597671439071
isolation precautions2.0597671439071
steroids?and persons2.0597671439071
guo a2.0597671439071
potential risks2.0597671439071
blinded rct2.0597671439071
third rct2.0597671439071
pcr assay2.0597671439071
potential barriers2.0597671439071
red blisters2.0597671439071
challenging cases2.0597671439071
arora a2.0597671439071
intact persons2.0597671439071
rockwitz k2.0597671439071
continued new vesicle formation2.0565711885958
results of pcr assay2.0396489026555
gnann jw jr2.0396489026555
0.5-ml intramuscular injection2.0396489026555
focal neurologic findings2.0396489026555
concomitant administration of zostavax2.0396489026555
general practice2
inferior pharmacokinetic characteristics2
u.s. food2
anti?tumor necrosis factor2
primary dermatome2
cerebral arteries2
uptake of rzv2
nondrug therapies2
white je1.9679896712654
zhang q1.9679896712654
life-threatening allergy1.9679896712654
sutphin je1.9679896712654
hematopoietic cell transplantation recipients1.9668942118313
duke university medical center1.9579730911015
magnetic resonance angiography1.9441612972397
richter c1.9343364202677
johnson g1.9343364202677
bakri sj1.9343364202677
jacobsen sj1.9343364202677
vesikari t1.9343364202677
pilishvili t1.9343364202677
soong sj1.9343364202677
topical creams1.9343364202677
topical capsaicin1.9343364202677
tran h1.9343364202677
weiss h1.9343364202677
einsele h1.9343364202677
common sentinel1.9343364202677
gzoster h1.9343364202677
chiller t1.9343364202677
kiefe c1.9343364202677
ulbricht c1.9343364202677
claeys c1.9343364202677
clayton t1.9343364202677
disseminated rashes1.9343364202677
adult u.s. population1.9063685859939
middle cerebral artery1.9063685859939
zhu c. corticosteroids1.9063685859939
clear vesicles1.8612097182042
epidural steroids1.8612097182042
noncontiguous dermatomes1.8612097182042
time frame1.8612097182042
strict isolation1.8612097182042
many people1.8612097182042
previous exposure1.8612097182042
role of corticosteroids1.8612097182042
case reports1.8612097182042
body fight1.8612097182042
shpilberg o1.8612097182042
over-the-counter medications1.8612097182042
small children1.8612097182042
immunogenicity profile1.8612097182042
appearance of blisters1.8612097182042
reports grants1.8612097182042
placebo groups1.8612097182042
several days1.8612097182042
affected dermatome1.8612097182042
morrison va1.8612097182042
godeaux o1.8612097182042
eye evaluation1.8612097182042
additional therapies1.8612097182042
high sensitivity1.8612097182042
approved valacyclovir dosage1.8493111942973
mmwr surveill summ1.8493111942973
consistent diagnostic criterion1.8493111942973
transient ischemic attacks1.8493111942973
basic symptomatic measures1.8493111942973
antimicrob agents chemother1.8493111942973
short-term persistence substudy1.8171205928321
small vessel vasculitis1.8171205928321
short-acting narcotic analgesics1.7817974362807
phys rev lett1.7817974362807
american academy of ophthalmology1.7817974362807
san miguel jf1.7817974362807
stokley s1.7782794100389
yeh s1.7782794100389
aboutlabeti s1.7782794100389
moeckesch b1.7782794100389
nahlik je1.7782794100389
kerzner b1.7782794100389
medlineplus information1.7782794100389
nagel ma1.7782794100389
cerebrovascular events1.7782794100389
dimopoulos ma1.7782794100389
thorne je1.7782794100389
auricle?indicate ramsay hunt syndrome1.7692284081335
author thanks jennifer f. wilson1.7411011265923
wade jc1.7320508075689
over-the-counter medicines1.7320508075689
preferred test1.7320508075689
preferred alternative1.7320508075689
2-dose regimen1.7320508075689
local reactions1.7320508075689
as-needed basis1.7320508075689
curr opin neurol1.6983813295649
past several decades1.6983813295649
mg/kg of body weight1.6983813295649
mg of methylprednisolone acetate1.6983813295649
van wijck aj1.6983813295649
internal carotid artery1.6983813295649
van essen ga1.6983813295649
general feeling1.6817928305074
toxic dermatitis1.6817928305074
ambinder rf1.6817928305074
eligible people1.6817928305074
corey l1.6817928305074
chamberlin cj1.6817928305074
clusters of vesicles1.6817928305074
rare disorder1.6817928305074
research setting1.6817928305074
ophthalmology consultation1.6817928305074
stolker rj1.6817928305074
previous version1.6817928305074
high-dose steroids1.6817928305074
rare occasions1.6817928305074
positive results1.6817928305074
smeeth l1.6817928305074
subsequent pustulation1.6817928305074
absence of pleocytosis1.6817928305074
lymphocytic pleocytosis1.6817928305074
kalkman cj1.6817928305074
three times1.6817928305074
ragozzino mw1.6817928305074
acosta cj1.6817928305074
mononuclear pleocytosis1.6817928305074
bortezomib-based therapies1.6817928305074
million people1.6817928305074
prospective fashion1.6817928305074
analgesic medications1.6817928305074
wallace mr. detection1.5874010519682
cool astringent soaks1.5874010519682
comas j. observation1.5874010519682
health-related quality of life1.5874010519682
private insurance plans1.5874010519682
english word gbelt1.5874010519682
st sauver jl1.5874010519682
sensory neurons1.5650845800733
controlled-release oxycodone1.5650845800733
types of vaccines1.5650845800733
such manifestations1.5650845800733
elam-evans ld1.5650845800733
connor jd1.5650845800733
2-dose requirement1.5650845800733
mg of bupivacaine1.5650845800733
outpatient basis1.5650845800733
standard precautions1.5650845800733
localized sensations1.5650845800733
adult populations1.5650845800733
cobo lm1.5650845800733
kurland lt1.5650845800733
specific treatments1.5650845800733
perry ta1.5650845800733
latent state1.5650845800733
susceptible infants1.5650845800733
friedman dj1.5650845800733
huff jc1.5650845800733
cohen ji1.5650845800733
shafran sd1.5650845800733
bone cancer1.5650845800733
schoenberger sd1.5650845800733
rice as1.5650845800733
lopez as1.5650845800733
frequency increases1.5650845800733
cheng e1.5650845800733
williams ww1.5650845800733
mcquillan gm1.5650845800733
direct invasion1.5650845800733
white race1.5650845800733
gelb ld1.5650845800733
similar syndrome1.5650845800733
local anaesthetics1.5650845800733
mcgill ji1.5650845800733
virus?related vasculitis1.5650845800733
perry ho1.5650845800733
grohskopf la1.5650845800733
dermatomal distribution1.5650845800733
shapiro e1.5650845800733
frank infarction1.5650845800733
plant exposure1.5650845800733
williams hm1.5650845800733
galea sa1.5650845800733
meyers jd1.5650845800733
lee gm1.5650845800733
weakened immunity1.5650845800733
billing challenges1.5650845800733
brain infarction1.5650845800733
experienced ophthalmologist1.5650845800733
sensory nerves1.5650845800733
good alternative1.5650845800733
li q1.5650845800733
wollan pc1.5650845800733
intravitreal antivirals1.5650845800733
experienced physicians1.5650845800733
mcneil sa1.5650845800733
special considerations1.5650845800733
crane la1.5650845800733
cost?benefit considerations1.5650845800733
looney dj1.5650845800733
fluorescent antigen1.4142135623731
harvey pr1.4142135623731
disease-related immunosuppression1.4142135623731
neural blockade1.4142135623731
belongia ea1.4142135623731
khuageva nk1.4142135623731
lu pj1.4142135623731
fact sheet1.4142135623731
allogenic transplants1.4142135623731
straus se1.4142135623731
singleton ja1.4142135623731
keatley rm1.4142135623731
female sex1.4142135623731
significant fever1.4142135623731
dooling kl1.4142135623731
moons kg1.4142135623731
sharrar rg1.4142135623731
chu cp1.4142135623731
thomas sl1.4142135623731
dorsal root1.4142135623731
hales cm1.4142135623731
riley le1.4142135623731
mcdermott mp1.4142135623731
barbano rl1.4142135623731
hematogenous route1.4142135623731
quantum-well structures1.4142135623731
tseng hf1.4142135623731
proximal branches1.4142135623731
sweet ar1.4142135623731
andersen pl1.4142135623731
gershon aa1.4142135623731
madkan vk1.4142135623731
schmid ds1.4142135623731
only contraindication1.4142135623731
light touch1.4142135623731
gebremeskel bg1.4142135623731
known correlation1.4142135623731
oligoclonal bands1.4142135623731
nucleic acids1.4142135623731
neurotrophic keratitis1.4142135623731
average interval1.4142135623731
hurley lp1.4142135623731
t-cell count1.4142135623731
ortega-sanchez ir1.4142135623731
arbeit rd1.4142135623731
pappas pg1.4142135623731
lindley mc1.4142135623731
rheumatoid arthritis1.4142135623731
melton lj1.4142135623731
joesoef mr1.4142135623731
human services1.4142135623731
bmj open1.4142135623731
arterial stenosis1.4142135623731
barbarash ra1.4142135623731
cerebrospinal fluid1.4142135623731
protein level1.4142135623731
daley mf1.4142135623731
vitreous humor1.4142135623731
subacute delirium1.4142135623731
lasting damage1.4142135623731
hutchinson sign1.4142135623731
opstelten w1.4142135623731
schwarz tf1.4142135623731
medline plus1.4142135623731
loose-fitting clothing1.4142135623731
boardman kd1.4142135623731
beutner kr1.4142135623731
sawyer mh1.4142135623731
mandal bk1.4142135623731
chaves ss1.4142135623731
shanabrook bv1.4142135623731
likelihood of adherence1.4142135623731
mri scans1.4142135623731
simberkoff ms1.4142135623731
60-year period1.4142135623731
wu yn1.4142135623731
hill ha1.4142135623731
auditory canal1.4142135623731
multiple myeloma1.4142135623731
pregnant women1.4142135623731
out-of-pocket payments1.4142135623731
tool kit1.4142135623731
clinician look1.4142135623731
garner js1.4142135623731
north carolina1.4142135623731
murray av1.4142135623731
burden of illness1.4142135623731
mertz gj1.4142135623731
ready availability1.4142135623731
hearing impairments1.4142135623731
submitted work1.4142135623731
forbes hj1.4142135623731
temporal increase1.4142135623731